News | Radiation Therapy | January 25, 2017

Study Supports Elekta Gamma Knife for Treatment of Large or Complex Brain Tumors

Results show Gamma Knife spares normal brain tissue and delivers higher target dose compared with linac-based radiotherapy platforms

Elekta Gamma Knife, hypofractionated radiosurgery, large or complex brain tumors, Journal of Neurosurgery study

January 25, 2017 — Elekta announced new data demonstrating Leksell Gamma Knife better spares healthy brain tissue and delivers a higher radiation dose compared to linear accelerator (linac)-based delivery methods. The results, evaluating patients undergoing radiosurgery for large or complex brain tumors, were published in the Journal of Neurosurgery.

The study compared treatment planning capabilities of three radiosurgery delivery systems in 10 consecutive patients with single brain tumors who received treatment between 2014 and 2015 using volumetric modulated arc therapy (VMAT), a type of linac-based delivery. Radiotherapy data from these patients’ prior treatments were exported to the Gamma Knife[i] or CyberKnife[ii] treatment planning systems and re-planned for delivery with Gamma Knife, CyberKnife and VMAT modalities.

Treatment replanning was conducted in a blinded and independent fashion. The three systems were compared in each patient and assessed for dose distribution, conformity index (CI, a measure of the relationship between treated target tissue and untreated healthy tissue), gradient index (GI, a measure of dose decrease outside the target area), distribution of the prescribed radiation dose, and the volume of normal brain tissue receiving a radiation dose of 15 Gy, 10 Gy or 5 Gy.

Results show the three modalities had similar CI and a significant difference in GI (p<0.0002) favoring Gamma Knife. Significant differences were also observed for dose distribution, with Gamma Knife showing greater central target dosing compared with CyberKnife and VMAT. Among patients treated with Gamma Knife, significantly less healthy brain tissue received a dose of 15 Gy compared with CyberKnife or VMAT. Results were similar for Gamma Knife and CyberKnife at the 10 Gy and 5 Gy doses, and both were significantly lower than the VMAT group.

“The results of this study demonstrate that the precise beam created by the fixed radiation sources of Leksell Gamma Knife results in significant tissue-sparing benefits to patients with large or complex brain tumors,” said Lijun Ma, Ph.D., DABMP, FAAPM, professor in the Department of Radiation Oncology at the University of California, San Francisco and senior author on the study. “Importantly, this benefit is achieved without compromising effective dosing to target tumor tissue.”

The study also underscores the differences in dose delivered to healthy brain tissue that can result when similar doses are delivered to the periphery of the tumor. Prior studies have shown the dose delivered to normal brain tissue increases steeply as tumor target size increases. Study results suggest that Gamma Knife reduces the dose to healthy tissue when using hypofractionated radiosurgery to treat large brain tumors. The authors note that further studies investigating the normal brain-tolerable dose of hypofractionated radiosurgery are needed to determine optimal dosing and fractionation practices.

With Elekta’s latest-generation radiosurgery system, Leksell Gamma Knife Icon, which includes stereotactic imaging and a new frameless motion management system, Gamma Knife treatment may be expanded to a broader range of brain lesions.

For more information: www.thejns.org

 

[i] Leksell GammaPlan V10.2 for the Perfexion Extend system

[ii] Multiplan V4.5 for the CyberKnife VSI System

 

Dong, P., Perez-Andujar, A., Pinnaduwage, D., Braunstehttp://10.3171/2016.7.GKS16881in, S., et al. "Dosimetric characterization of hypofractionated Gamma Knife radiosurgery of large or complex brain tumors versus linear accelerator-based treatments," Journal of Neurosurgery. Published December 2016. DOI: 10.3171/2016.7.GKS16881

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...